Central nervous system disorders reported include paresthesia, dizziness, lightheadedness and feeling faint, all of these usually resolved on cessation of therapy.
Somnolence, insomnia and vertigo have been reported rarely. Reversible mental confusion, agitation, depression and hallucinations have occurred predominantly in severely ill patients.
Other adverse events reported rarely include arthralgia and myalgia, blurred vision, taste disturbances, peripheral oedema, hyponatremia, blood disorders including agranulocytosis, leucopenia, thrombocytopenia, pancytopenia, anaphylactic shock, malaise, fever, bronchospasm, encephalopathy in patients with pre-existing severe liver disease, hepatitis with or without jaundice, rarely hepatic failure and interstitial nephritis which has resulted in acute renal failure.
View ADR Monitoring Form